This article reviews the manuscripts in this issue and summarizes the conclusion that erythropoiesis-stimulating agents are safe and effective in alleviating anemia, diminishing transfusion use, and improving quality of life in symptomatic anemic patients when used according to current guidelines.
No takes yet. Share an insight, caveat, or question.
Matti Aapro (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: